No tox species; sublethally irradiated immunodeficient mice (xenogeneic GVHD proof-of-concept) plus published murine literature
“In the applicant’s POC studies using xenogeneic models, co-administration of human donor Tregs with Tcons demonstrated dose-dependent GVHD inhibition in sub-lethally irradiated immunodeficient mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Why that species
Immunodeficient mice allow human Tcon-induced xenogeneic GVHD and Treg mitigation; no relevant tox species stated
“evaluating the ability of human Tcons to induce xenogeneic GVHD”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Surrogate molecule
Yes: published murine HSC, Treg, Tcon studies used as mechanism-of-action support; human cells tested in mouse xenograft
“Instead, in Module 4 of the BLA, the applicant submitted 45 publications delineating the MOAs of HSCs (mouse and human), Tregs (mouse), Tcons (mouse), and their combinations (mouse).”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗